SGLT2抑制剂抗恶性肿瘤研究进展

Research progress of SGLT2 inhibitors against malignant tumors

越来越多的证据显示, 糖尿病与肿瘤发生、发展密切关联, 降糖药物与肿瘤的相关性, 尤其是降糖药物是否同时具备抗肿瘤作用逐渐成为内分泌和肿瘤研究的新热点。近来, 一种新型口服降糖药钠-葡萄糖转运体(SGLT2)抑制剂被发现同时具备抑制肿瘤发生、发展的作用, 该文对SGLT2抑制剂与肿瘤的相关性, 尤其是SGLT2抑制剂抗肿瘤作用机制进行归纳综述, 以期为降糖药物SGLT2抑制剂的抗肿瘤相关机制研究提供线索。

More and more evidence shows that diabetes is closely related to the occurrence and development of cancer.The correlation between anti-diabetic agents and tumors,especially whether anti-diabetic agents have anti-tumor effect,has become a new hot spot in the field of endocrine and tumor research.Recently,SGLT2 inhibitors,as a new oral anti-diabetic agents,have been shown to inhibit the occurrence and development of cancer.In this review,the correlation between anti-diabetic agents and tumors,especially the anti-tumor mechanism of SGLT2 inhibitors,is summarized,in order to provide clues to the research of anti-tumor mechanism of SGLT2 inhibitors.